Clinical Trial Update: A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating pharmacokinetics, metabolism, and excretion of GS-5806 (Presatovir) in respiratory syncytial virus infection; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Presatovir (GS-5806)

Snippet

Sponsor: Gilead Sciences | Conditions: RSV Infection | Phase 1 | Status: COMPLETED